Johnson & Johnson Medical China Launches Locally Manufactured Next-Gen Antibacterial VICRYL® Plus Absorbable Sutures

Suzhou, December 17, 2021 /PR Newswire/ -- Recently, Johnson & Johnson Medical's Chinese-manufactured Ethicon new generation antibacterial Vicryl absorbable sutures (VICRYL^®Plus) successfully rolled off the production line and was delivered at the Johnson & Johnson Suzhou Industrial Park. As the first domestically manufactured surgical suture with triclosan antimicrobial coating in China, the new-generation antibacterial Vicryl embodies the global innovative expertise of Johnson & Johnson and the advanced technology of Chinese manufacturing. It will respond more swiftly and efficiently to the growing and evolving surgical medical needs of the Chinese market.

"Surgical sutures are the origin of innovation in Johnson & Johnson's more than 130-year history. The successful delivery and launch of the China-manufactured antibacterial Vicryl marks a brand-new milestone in Johnson & Johnson Medical’s high-end intelligent manufacturing in China, and further signifies that Johnson & Johnson Medical continues to empower through innovation, accelerating its contribution to 'Healthy China'!" said Song Weiqun, Global Senior Vice President of Johnson & Johnson and Chairman of Johnson & Johnson China. "The Chinese market has strong development potential, and the public's demand for high-quality medical services is becoming increasingly diversified, which will continuously inject new momentum into Johnson & Johnson's long-term sustainable development in China. With the comprehensive capabilities of Johnson & Johnson Medical’s Suzhou Integrated Industrial Park, we will continue to deliver high-quality innovative solutions, creating more value for patients and healthcare professionals in China."

The new generation of antibacterial Vicryl absorbable sutures is the first Chinese-manufactured triclosan-coated antibacterial suture, which helps inhibit bacterial colonization on the suture and reduce the risk of surgical site infections, benefiting patients. Johnson & Johnson Medical introduced the advanced manufacturing process of this innovative product to China and began production in Suzhou. This not only fills the current industry gap in the production of triclosan-coated antibacterial sutures in China but also promotes the implementation of world-class quality control standards in China, supporting the continuous upgrading and vigorous development of China's healthcare industry.

Currently, Johnson & Johnson has a total of nine supply chain bases in China, including medical devices, pharmaceuticals, and consumer goods. Among them, the Johnson & Johnson Medical Suzhou Industrial Park is the largest medical device industrial park in China, integrating comprehensive businesses such as research and development, manufacturing, technological innovation and collaboration, and shared services, playing a significant role in the global supply chain system. In addition to producing and supplying medical device products needed for the global market, this base has also successively delivered innovative products such as orthopedic spinal implants, linear cutting staplers, laparoscopic staplers, and the 4K ultra-high-definition endoscopic imaging system, serving customers and patients in China.

As a global leader in the healthcare industry, Johnson & Johnson began large-scale production of sterile sutures in 1887. For over a century, Johnson & Johnson has consistently focused on innovation breakthroughs, infusing more technology and intelligence into medical products, including surgical sutures. While helping patients worldwide regain health, the company has also led and driven the development of the healthcare industry. In the future, Johnson & Johnson will introduce a series of medical innovation solutions, leveraging China's high-end intelligent manufacturing and supply chain systems with global empowerment and collaboration, to accelerate support for "Healthy China."”。